sing one dose Pfizer to boost immunity after full vaccination with AstraZeneca in cancer patients

Phase 1

• Conditions: Onco-hematological patients; Therapeutic area: Body processes [G] - Immune system processes [G12]

• Registration Number: EUCTR2021-003573-58-BE
• Lead Sponsor: Antwerp University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-07-16
• Last Update Posted: 7 February 2022

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 182

Inclusion Criteria

•Patients with oncological or hematological malignancy
•Vaccinated with priming and boosting ChAd-0x1-S vaccine
•Ability to provide informed consent

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 100
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 100

Exclusion Criteria

•Women who are pregnant or breastfeeding
•Immune deficiency not related to cancer or cancer treatment
•Allergy (multiple)

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified